Quality standard
Quality statement 2: Staging using FDG-PET-CT
Quality statement 2: Staging using FDG-PET-CT
Quality statement
Young people and adults with specific subtypes of non-Hodgkin's lymphoma have staging using fluorodeoxyglucose-positron emission tomography-CT (FDG-PET-CT).
Rationale
Imaging before treatment is important to define the disease stage and enable appropriate therapy. Metabolic imaging with FDG-PET-CT is more accurate than CT imaging alone for detecting the disease site in several specific histological subtypes of non-Hodgkin's lymphoma.
Quality measures
The following measures can be used to assess the quality of care or service provision specified in the statement. They are examples of how the statement can be measured, and can be adapted and used flexibly.
Structure
Evidence of local arrangements to ensure that young people and adults with specific subtypes of non-Hodgkin's lymphoma have staging using FDG-PET-CT.
Data source: Local data collection.
Process
a) Proportion of young people and adults with stage I diffuse large B-cell lymphoma who have staging using FDG-PET-CT.
Numerator – the number in the denominator who have staging using FDG-PET-CT.
Denominator – the number of young people and adults with stage I diffuse large B-cell lymphoma.
Data source: Local data collection.
b) Proportion of young people and adults with stage I or localised stage II follicular lymphoma for whom radiotherapy would be technically possible who have staging using FDG-PET-CT.
Numerator – the number in the denominator who have staging using FDG-PET-CT.
Denominator – the number of young people and adults with stage I or localised stage II follicular lymphoma for whom radiotherapy would be technically possible.
Data source: Local data collection.
c) Proportion of young people and adults with stage I or II Burkitt lymphoma with other low-risk features who have staging using FDG-PET-CT.
Numerator – the number in the denominator who have staging using FDG-PET-CT.
Denominator – the number of young people and adults with stage I or II Burkitt lymphoma with other low-risk features.
Data source: Local data collection.
What the quality statement means for different audiences
Service providers (specialist regional centres) have processes in place to ensure that young people and adults with specific subtypes of non-Hodgkin's lymphoma have FDG-PET-CT for staging.
Healthcare professionals (such as clinical oncologists) use FDG-PET-CT for accurate staging of specific subtypes of non-Hodgkin's lymphoma in young people and adults.
Commissioners ensure that they commission services in which young people and adults with specific subtypes of non-Hodgkin's lymphoma have FDG-PET-CT for staging.
Young people and adults with certain types of non-Hodgkin's lymphoma have a special scan called a FDG-PET-CT scan to show where the cancer cells are in the body and confirm the stage of the cancer. FDG-PET-CT scans are particularly useful for people who have been diagnosed with types of lymphoma called large B-cell lymphoma, follicular lymphoma and Burkitt lymphoma.
Source guidance
Non-Hodgkin's lymphoma: diagnosis and management. NICE guideline NG52 (2016), recommendation 1.2.1
Definitions of terms used in this quality statement
Specific subtypes of non-Hodgkin's lymphoma
FDG-PET-CT imaging should be offered to young people and adults with:
-
stage I diffuse large B‑cell lymphoma
-
stage I or localised stage II follicular lymphoma for whom radiotherapy would be technically possible (if the disease is thought to be encompassable within a radiotherapy field)
-
stage I or II Burkitt lymphoma with other low‑risk features.
[Adapted from NICE's guideline on non-Hodgkin's lymphoma: diagnosis and management, recommendation 1.2.1]